220 related articles for article (PubMed ID: 29080343)
1. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
2. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
3. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
4. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
[TBL] [Abstract][Full Text] [Related]
5. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
Arab JP; Karpen SJ; Dawson PA; Arrese M; Trauner M
Hepatology; 2017 Jan; 65(1):350-362. PubMed ID: 27358174
[TBL] [Abstract][Full Text] [Related]
6. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis.
Hu L; Zhou Z; Deng L; Ren Q; Cai Z; Wang B; Li Z; Wang G
J Pharm Pharmacol; 2020 Nov; 72(11):1564-1573. PubMed ID: 32734608
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
8. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
Xu JY; Li ZP; Zhang L; Ji G
World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
[TBL] [Abstract][Full Text] [Related]
9. Role of FXR in the development of NAFLD and intervention strategies of small molecules.
Long J; Xu Y; Zhang X; Wu B; Wang C
Arch Biochem Biophys; 2024 Jul; 757():110024. PubMed ID: 38703803
[TBL] [Abstract][Full Text] [Related]
10. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
[TBL] [Abstract][Full Text] [Related]
11. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
Chiang JYL; Ferrell JM
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
[TBL] [Abstract][Full Text] [Related]
12. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
13. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
14. The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids.
Gottlieb A; Bechmann L; Canbay A
Ann Hepatol; 2018; 17(3):340-341. PubMed ID: 29735794
[TBL] [Abstract][Full Text] [Related]
15. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
17. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
[TBL] [Abstract][Full Text] [Related]
18. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
19. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
[TBL] [Abstract][Full Text] [Related]
20. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]